

May 28, 2025

Corporate Relationship Department
BSE Limited,
PJ Towers, Dalal Street,
Mumbai- 400001

Dear Sirs,

Sub: Outcome of the Board meeting held on May 28, 2025
Ref: Script Code: 526783

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") we wish to inform that the Board of Directors of the Company at its meeting held today i.e. on Wednesday, May 28, 2025, commenced at 12.30 p.m. and concluded at 02:00 p.m. *inter alia*, considered and approved the following:

i) Audited Financial Results:

The Audited Financial Results of the Company for the year ended March 31, 2025 and the financial results for the quarter ended March 31, 2025. Copy of the same is enclosed along with the Reports of the Statutory Auditors thereon and a declaration by the Chief Financial Officer of the Company that the said Reports of Statutory Auditors are with an unmodified opinion.

ii) Final Dividend:

Recommended a Final dividend of Rs. 3.50/- per equity share of Rs.10/- each fully paid-up, (35%) for the financial year 2024-25 subject to approval of the Members at the ensuing Annual General Meeting. The Dividend shall be paid/ dividend warrant shall be dispatched to the Members within 30 days of its approval by the Members at the ensuing Annual General Meeting.

The above final dividend is in addition to the Interim Dividend at Rs.2.50/- of Rs.10/- each fully paid-up, (25%) that was declared by the Board at its meeting held on October 29, 2025, and the same was paid on November 21, 2024. With this recommendation, the total dividend for the year ended March 31, 2025, aggregates to Rs. 6.00/- per equity share of Rs.10/- each fully paid-up, (60%).

iii) Appointment of Statutory Auditors of the Company:

Appointment of M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, with ICAI Firm Registration No. 101049W/E300004, as Statutory Auditor of the Company in terms of Section 139 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 on recommendation of Audit Committee for undertaking the Statutory Audit of the Company for a period of 5 (Five) consecutive financial years from the conclusion of the 31st Annual General Meeting till the conclusion of the 36th Annual General Meeting, i.e. from 2025-26 to 2029-30; subject to the approval of the members at the ensuing Annual General Meeting of the Company.

Dr. Agarwal's Eye Hospital Limited

Regd. & Corporate Office

3rd Floor, Buhari Towers, No.4 Moores Road, Off Greaves Road, Near Asan Memorial School, Chennai - 600 006.

Tel: +91 44 4378 7777 | +91 44 4378 7778 | CIN: L85110TN1994PLC027366 | GST No: 33AAACD2373G1Z2

Email: info@dragarwal.com | Website: www.dragarwal.com

iv) **Appointment of Secretarial Auditor of the Company:**

Appointment of Mr. Subramanian Chandrasekar, (Membership No. FCS 6773 & COP 13761) Practising Company Secretary, as Secretarial Auditor of the Company, based on the recommendation of the Audit Committee, for a period of 5 (Five) consecutive financial years i.e. from 2025-26 to 2029-30, subject to the approval of the members at the ensuing Annual General Meeting of the Company.

v) **Reappointment of Dr. Amar Agarwal as the Chairman cum Managing Director of the Company:**

Based on the recommendation of the Nomination and Remuneration Committee, Dr. Amar Agarwal (DIN:00435684) is reappointed as Chairman cum Managing Director of the Company along with approval of remuneration for a period of 3 years with effect from October 01, 2025, and shall hold office till September 30, 2028; subject to approval of the members at the ensuing Annual General Meeting of the Company.

vi) **Reappointment of Dr. Athiya Agarwal as the Whole-Time of the Company:**

Based on the recommendation of the Nomination and Remuneration Committee, Dr. Athiya Agarwal (DIN:01365659) is reappointed as the Whole-time Director of the Company along with approval of remuneration for a period of 3 years with effect from October 01, 2025, and shall hold office till September 30, 2028; subject to approval of the members at the ensuing Annual General Meeting of the Company.

Additional information as required under Regulation 30 of SEBI Listing Regulations read with SEBI master Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding the aforesaid appointments/reappointments are enclosed. Pursuant to Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, it has been confirmed that Dr. Amar Agarwal and Dr. Athiya Agarwal are not disqualified or debarred from being appointed as a Director of the Company by SEBI or MCA or any other authority.

The Company has made arrangements for the release of the Audited Financial Results for the year ended March 31, 2025, in the newspaper as per the requirement of the SEBI (LODR) Regulation, 2015, and the same shall also be hosted on the website of the Company. Kindly take the above information on record.

Thanking you,

Yours sincerely

For **Dr. Agarwal's Eye Hospital Limited**

Meenakshi Jayaraman

Company Secretary and Compliance Officer

Encl: a/a

Annexure – Disclosure under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 – Brief Profile of the Directors

Name of the Director	Dr. Amar Agarwal (DIN: 00435684)	Dr. Athiya Agarwal (DIN: 01365659)
Reason for Change	Reappointment as Chairman cum Managing Director, subject to approval of members at the ensuing Annual General Meeting.	Reappointment as Whole-time Director, subject to approval of members at the ensuing Annual General Meeting
Date of appointment/ reappointment and term of appointment/ reappointment	With effect from October 01, 2025, for a period of 3 years;	With effect from October 01, 2025, for a period of 3 years
Date of birth	20-07-1960	04-07-1955
Date of first appointment	22-04-1994	09-05-1994
Qualification	MS, F.R.C.S, F.R.C Ophth. (Lon)	M.D. F.R.S.H (Lon.) D.O.
Brief Profile & Expertise	Dr. Amar Agarwal holds a master's degree in surgery from Gujarat University. He was previously the president of International Society of Refractive Surgery, a partner of the American Academy of Ophthalmology. He is a widely respected Ophthalmic surgeon, Inventor of Phakonit, Microphakonit and PDEK a significant milestone in cataract surgery.	Dr. Athiya Agarwal holds a bachelor's degree in medicine from Madras Medical College and a master's degree in ophthalmology from Gujarat University. She is a widely respected ophthalmic surgeon with over 47 years of experience in the field of ophthalmology.
Directorships held in other Companies	1. Dr. Agarwal's Health Care Limited 2. Dr. Agarwal's Eye Institute Private Limited 3. Aditya Jyot Eye Hospital Private Limited	1. Dr. Agarwal's Eye Institute Private Limited
Relationship Between Directors/ KMP inter-se	Dr. Amar Agarwal is the spouse of Dr. Athiya Agarwal and father of Dr. Adil Agarwal	Dr. Athiya Agarwal is the spouse of Dr. Amar Agarwal and mother of Dr. Adil Agarwal

Dr. Agarwal's Eye Hospital Limited

Regd. & Corporate Office

3rd Floor, Buhari Towers, No.4 Moores Road, Off Greams Road, Near Asan Memorial School, Chennai – 600 006.

Tel: +91 44 4378 7777 | +91 44 4378 7778 | CIN: L85110TN1994PLC027366 | GST No: 33AAACD2373G1Z2

Email: info@dragarwal.com | Website: www.dragarwal.com

Annexure – Disclosure under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 - Brief profile of the Statutory Auditor and Secretarial Auditor

Sl.No.	Particulars	M/s. S. R. Batliboi & Associates LLP, Chartered Accountants	Mr. Subramanian Chandrasekar, Practising Company Secretary
1.	Reason for Change viz. appointment	The current term of the existing Statutory Auditor, M/s. Deloitte Haskins & Sells (FRN: 008072S), is expiring at the conclusion of the ensuing Annual General Meeting (AGM). The Audit Committee and the Board of Directors have recommended the appointment of M/s. S.R. Batliboi & Associates LLP, as the Statutory Auditors of the Company due to expiry of term of appointment of the existing statutory auditors M/s. Deloitte Haskins & Sells, Chartered Accountants	Appointment of Mr. Subramanian Chandrasekar, peer-reviewed Practising Company Secretary as the secretarial auditor of the Company pursuant to the amended Regulation 24A of the SEBI Listing Regulations.
2.	Date of appointment and term of appointment	May 28, 2025, approved the appointment of Statutory Auditors, for a term of five consecutive years commencing from the conclusion of the 31 st AGM till the conclusion of the 36 th AGM of the Company; subject to approval of the members at the ensuing Annual General Meeting.	May 28, 2025, approved the appointment of Secretarial Auditor, for a term of five consecutive years commencing from FY 2025-26 till FY 2029-30; subject to approval of the members at the ensuing AGM.
3.	Brief profile	S. R. Batliboi & Associates LLP (“the Firm/SRB”), a limited liability partnership firm incorporated in India, is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India (“ICAI”) with (ICAI Firm Registration No. 101049W/E300004). The Firm is part of S. R. Batliboi & Associates, a network of firms registered with the ICAI. The Firm was established in 1949 with its registered office in Kolkata and has offices across key cities in India. The Firm has a valid Peer Review certificate. All the network firms including the Firm are primarily engaged in providing audit and assurance services to its clients. They along-with its network firms audit several large listed and private companies across diverse market segments including Industrial, Infrastructure, Consumer Products, Financial Services, Technology, Media and Entertainment, Telecommunications and Professional Services.	Mr. Subramanian Chandrasekar is a Fellow Member of the Institute of Company Secretaries of India (Membership No. FCS 6773 & COP 13761) and an Associate Member of The Institute of Chartered Governance, United Kingdom with two (2) decades of experience in governance and compliance. He also holds a Masters Degree in Business Administration and Financial Management. He has been providing knowledge-based services to various companies in the fields of corporate compliance, regulatory filings and advisory services.
4.	Relationships between directors	Not applicable	Not applicable

Dr. Agarwal's Eye Hospital Limited

Regd. & Corporate Office

3rd Floor, Buhari Towers, No.4 Moores Road, Off Greaves Road, Near Asan Memorial School, Chennai - 600 006.

Tel: +91 44 4378 7777 | +91 44 4378 7778 | CIN: L85110TN1994PLC027366 | GST No: 33AAACD2373G122

Email: info@dragarwal.com | Website: www.dragarwal.com

May 28, 2025

Corporate Relationship Department
BSE Limited, PJ Towers, Dalal Street,
Mumbai- 400001

Dear Sirs

Sub: Declaration in respect of Statutory Auditors Report with Unmodified Opinion- Reg.

Ref: 1) Regulation 33 of the SEBI (LODR) Regulation, 2015

2) Script Code: 526783


We hereby declare that the Statutory Auditors of the Company M/s. Deloitte Haskins & Sells (Firm Registration Number 008072S), Chartered Accountants, Chennai, have issued the Audit Report with Unmodified Opinion with respect to the Audited Financial Results for the financial year ended 31st March 2025.

Kindly take the above information on record.

Thanking you,

Yours truly

For Dr. Agarwal's Eye Hospital Limited


Yashwanth Venkat
Chief Financial Officer

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

Opinion and Conclusion

We have (a) audited the Financial Results for the year ended 31 March 2025 and (b) reviewed the Financial Results for the quarter ended 31 March 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Audited Financial Results for the Year Ended 31 March 2025 and Unaudited Financial Results for the Quarter Ended 31 March 2025" of **DR. AGARWAL'S EYE HOSPITAL LIMITED** (the "Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Financial Results for the year ended 31 March 2025:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Financial Results for the quarter ended 31 March 2025

With respect to the Financial Results for the quarter ended 31 March 2025 based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Financial Results for the quarter ended 31 March 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Deloitte Haskins & Sells

Basis for Opinion on the Audited Financial Results for the year ended 31 March 2025

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Financial Results for the year ended 31 March 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Financial Results for the year ended 31 March 2025 has been compiled from the related audited financial statements. This responsibility includes the preparation and presentation of the Financial Results for the quarter and year ended 31 March 2025 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Financial Results for the year ended 31 March 2025

Our objectives are to obtain reasonable assurance about whether the Financial Results for the year ended 31 March 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.



Deloitte Haskins & Sells

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Financial Results, including the disclosures, and whether the Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Financial Results of the Company to express an opinion on the Annual Financial Results.

Materiality is the magnitude of misstatements in the Annual Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.



Deloitte Haskins & Sells

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Financial Results for the quarter ended 31 March 2025

We conducted our review of the Financial Results for the quarter ended 31 March 2025 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- The Statement includes the results for the Quarter ended 31 March 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



R. Prasanna Venkatesh

R. Prasanna Venkatesh
Partner
Membership No. 214045
UDIN: 25214045BMNWHQ7196

Place: Chennai
Date: 28 May 2025

(Amount in INR Crores) except EPS

Statement of Audited Financial Results for the year ended 31st March 2025 and Unaudited Financial Results for the Quarter ended 31st March 2025

S.No.	Particulars	Quarter Ended		Year ended	
		31-Mar-25 (Refer Note 3)	31-Dec-24 Unaudited	31-Mar-24 (Refer Note 3)	31-Mar-25 Audited
1	Income				
	(a) Revenue from Operations	99.83	95.11	80.72	397.15
	(b) Other Income	0.10	2.31	2.46	5.09
	Total income	99.93	97.42	83.18	402.24
2	Expenses				
	(a) Purchase of Stock-in-Trade	9.03	10.89	8.85	43.11
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	1.61	(0.68)	(0.56)	(1.16)
	(c) Surgical Lens including other consumables	10.97	11.86	9.01	47.67
	(d) Consultancy Charges for Doctors	13.84	11.66	11.72	53.27
	(e) Employee Benefit Expenses	19.95	20.90	15.41	78.32
	(f) Finance Costs	2.89	3.85	2.03	13.44
	(g) Depreciation and Amortisation Expense	10.20	10.02	7.53	39.45
	(h) Other Expenses	12.84	14.86	11.85	57.44
	Total Expenses	81.33	83.36	65.84	331.54
3	Profit before tax (1-2)	18.60	14.06	17.34	70.70
	Tax Expense				
	- Current Tax (including tax pertaining to earlier years)	2.02	3.85	4.70	15.81
	- Deferred Tax (Net)	0.59	(0.19)	(0.15)	0.24
4	Total tax expenses	2.61	3.66	4.55	16.05
5	Net Profit after tax for the period (3-4)	15.99	10.40	12.79	54.65
6	Other Comprehensive Income				
	(a) Items that will not be reclassified to the Statement of Profit and Loss				
	- Actuarial (loss) / gain on defined benefit obligation	0.59	(0.12)	1.03	0.22
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	(0.15)	0.03	(0.27)	(0.06)
	Total Other Comprehensive Income / (loss) (net of tax)	0.44	(0.09)	0.76	0.16
7	Total Comprehensive Income / (Loss) (5+6)	16.43	10.31	13.55	54.81
8	Paid-up equity share capital (Face value INR 10/- each)	4.70	4.70	4.70	4.70
9	Reserves (Other Equity)				204.91
10	Earnings Per Equity Share (EPS) (Face value of INR 10/- each)				
	(a) Basic	34.02	22.13	27.21	116.28
	(b) Diluted	34.02	22.13	27.21	116.28
		(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)
	Additional Information:				
	Earnings before finance cost, depreciation, amortisation and tax (EBITDA) (Refer Foot Note (i))	31.69	27.93	26.90	123.59

Foot note:

(i) The company has presented information on EBITDA additionally as a part of the statement of financial results as defined above.



Agarwal



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

(Amount in INR Crores)

Balance Sheet			
S.No	Particulars	As at 31st March 2025 Audited	As at 31st March 2024 Audited
A	ASSETS		
1	Non-Current Assets		
	Property, Plant and Equipment	160.13	120.87
	Right to Use Assets	204.97	193.96
	Capital Work-In-Progress	127.98	97.44
	Goodwill	5.66	0.18
	Other Intangible Assets	22.43	0.62
	Financial Assets		
	Other Financial Assets	10.03	8.50
	Deferred Tax Assets (Net)	9.74	10.03
	Non Current Tax Assets (Net)	2.12	-
	Other Non-Current Assets	14.32	4.33
	Total Non-Current Assets	557.38	435.93
2	Current Assets		
	Inventories	13.40	9.75
	Financial Assets		
	Investments	12.63	-
	Trade Receivables	13.97	12.93
	Cash and Cash Equivalents	11.16	32.88
	Bank Balances other than Cash and Cash Equivalents	1.01	0.86
	Other Financial Assets	2.21	1.96
	Other Current Assets	1.56	1.45
	Total Current Assets	55.94	59.83
	Total Assets(1+2)	613.32	495.76
B	EQUITY AND LIABILITIES		
3	EQUITY		
	Equity Share Capital	4.70	4.70
	Other Equity	204.91	152.45
	Total Equity	209.61	157.15
4	LIABILITIES		
	Non-Current Liabilities		
	Financial Liabilities		
	Borrowings	81.77	44.46
	Lease Liabilities	223.86	203.59
	Other Financial Liabilities	2.33	2.36
	Provisions	8.77	7.43
	Total Non-Current Liabilities	316.73	257.84



Agarwal



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

(Amount in INR Crores)

Balance Sheet			
S.No	Particulars	As at 31st March 2025 Audited	As at 31st March 2024 Audited
5	Current Liabilities		
	Financial Liabilities		
	Borrowings	14.59	6.84
	Lease Liabilities	12.94	13.13
	Trade Payables		
	- Total outstanding dues of micro enterprises and small enterprises	3.59	4.62
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	26.61	27.22
	Other Financial Liabilities	22.33	20.28
	Other Current Liabilities	5.51	5.19
	Provisions	1.41	1.29
	Current tax liabilities (net)	-	2.20
	Total Current Liabilities	86.98	80.77
	Total Liabilities(4+5)	403.71	338.61
	Total Equity and Liabilities(3+4+5)	613.32	495.76

Notes:

- 1 The above financial results have been prepared in accordance with the Indian Accounting Standard ('Ind AS') notified under Section 133 of the Companies Act, 2013, read together with the Companies (Indian Accounting Standards) Rules, 2013 (as amended).
- 2 The above financial results have been reviewed by the Audit Committee and the same has been approved and taken on record by the Board of Directors at their meeting held on 28th May 2025.
- 3 The Financial results for the year ended 31st March 2025 have been audited by the statutory auditors of the Company. The figures for the quarter ended 31st March 2025 and the quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of the financial year ended 31st March 2025 and 31st March 2024 respectively and published year to date figures for the nine months ended 31st December 2024 and 31st December 2023 respectively which were subjected to limited review by the statutory auditors.
- 4 The Company operates in a single segment i.e. "Eye Care related sales and services" and does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
- 5 The Board of Directors at its meeting held on 28th May 2025 have recommended a final dividend of INR.3.5/per equity share, subject to the approval of Shareholders.

Place : Chennai
Date : 28th May 2025

By order of the Board

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684

Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

(Amount in INR Crores)

Cash flow Statement

Particulars	For the year ended 31st March 2025	For the year ended 31st March 2024
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax for the period	70.70	62.25
Adjusted for:		
(Profit)/ loss on sale/ discard of property, plant and equipment and other intangible assets (net)	0.16	0.23
Profit on termination of lease (Net)	(0.16)	
Allowances for expected credit loss (including bad debts written off)	0.39	0.86
Interest on acquisition liability	0.50	0.08
Depreciation and amortisation expense	39.45	26.61
Liabilities/ provisions no longer required written back	(1.58)	(1.72)
Profit on redemption of current investments/Fair Value changes	(0.88)	-
Interest income	(0.82)	(1.95)
Other Finance costs	12.94	7.04
Operating profit before working capital and other changes	120.70	93.40
Adjustments for (increase)/decrease in operating assets:		
Inventories	(3.65)	(3.75)
Trade receivables	(1.46)	(3.71)
Other financial assets - Non current	(0.73)	(0.70)
Other financial assets - Current	(0.29)	0.46
Other current assets	(0.11)	(1.20)
Adjustments for increase/(decrease) in operating liabilities:		
Trade payables	(0.05)	6.86
Other financial liabilities - Non current	(0.67)	1.26
Other financial liabilities - Current	(1.12)	8.15
Provisions	1.67	1.52
Other current liabilities	0.32	1.09
Cash generated from operations	114.61	103.38
Income Taxes paid (net of refunds)	(20.13)	(13.61)
Net cash generated from operating activities (A)	94.48	89.77
B. CASH FLOW FROM INVESTING ACTIVITIES		
Capital expenditure towards tangible and intangible assets (including capital advances, net of capital creditors)	(102.86)	(71.32)
Proceeds from Sale of Property, Plant and Equipment	0.41	1.00
Payment towards acquisition of business (including acquisition liabilities paid)	(18.48)	(0.50)
Increase in Bank balances not considered as Cash and cash equivalents	(0.16)	(0.14)
Interest Received on Fixed Deposit	0.06	0.92
Sale/Purchase of Investments	(11.75)	-
Net cash (used in) investing activities (B)	(132.78)	(70.04)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Borrowings	56.18	15.00
Repayment of Borrowings	(11.13)	(7.53)
Dividend paid (including tax thereon)	(2.35)	(2.58)
Finance costs paid on borrowings	(3.18)	(0.23)
Payment of lease liabilities	(22.94)	(18.89)
Net cash generated from/ (used in) financing activities (C)	16.58	(14.23)



Agarwal



Dr. Agarwal's Eye Hospital Limited
CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

(Amount in INR Crores)

Cash flow Statement

Particulars	For the year ended 31st March 2025	For the year ended 31st March 2024
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C) = (D)	(21.72)	5.50
Cash and cash equivalents at the beginning of the period (E)	32.88	27.38
Cash and cash equivalents at the end of the period (D + E) = (F)	11.16	32.88
Cash on hand	1.20	0.52
Balances with Banks	9.96	32.36
Cash and cash equivalents at the end of the period	11.16	32.88

Place : Chennai
Date : 28th May 2025



By order of the Board


Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in INR Crores) except EPS)

Statement of Audited Financial Results for the Year Ended 31st March 2025 and Unaudited Financial Results for the Quarter ended 31st March 2025

Particulars	Quarter Ended			Year ended	
	31-Mar-25 (Refer Note 2)	31-Dec-24 Unaudited	31-Mar-24 (Refer Note 2)	31-Mar-25 Audited	31-Mar-24 Audited
Revenue from Operations	99.83	95.11	80.72	397.15	319.30
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	18.60	14.06	17.34	70.70	62.25
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	18.60	14.06	17.34	70.70	62.25
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	15.99	10.40	12.79	54.65	46.36
Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	16.43	10.31	13.55	54.81	46.40
Paid-up Equity Share Capital (Face Value of INR 10/- each)	4.70	4.70	4.70	4.70	4.70
Reserves (Other Equity)				204.91	152.45
Earnings Per Share (for continuing and discontinued operations) (Face Value of INR 10/- each):					
(a) Basic	34.02	22.13	27.21	116.28	98.64
(b) Diluted	34.02	22.13	27.21	116.28	98.64
	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)	(Annualised)

Notes:

- 1) The above is an extract of the detailed format of Annual Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Annual Audited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).
- 2) The Financial results for the year ended 31st March 2025 have been audited by the statutory auditors of the Company. The figures for the quarter ended 31st March 2025 and the quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of the financial year ended 31st March 2025 and 31st March 2024 respectively and published year to date figures for the nine months ended 31st December 2024 and 31st December 2023 respectively which were subjected to limited review by the statutory auditors.

By order of the Board



M. J. J.

Place : Chennai
Date : May 28, 2025

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684